Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Novo Nordisk A/S
ISIN US6701002056
|WKN 866931
Market cap (in EUR)
176,571 m
Country
Denmark
Sector
Healthcare
Dividend yield
2.69%
Overview
Description
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Denmark
Financials
Key metrics
| Market capitalisation, EUR | 176,571 m |
| EPS, EUR | 3.68 |
| P/B ratio | 6.5 |
| P/E ratio | 10.7 |
| Dividend yield | 2.69% |
Income statement (2025)
| Revenue, EUR | 41,427 m |
| Net income, EUR | 13,730 m |
| Profit margin | 33.14% |
What ETF is Novo Nordisk A/S in?
There is 1 ETF which contains Novo Nordisk A/S.
| ETF | Weight | Investment focus | Fund size (in m EUR) |
|---|---|---|---|
| Harbor Health Care UCITS ETF Accumulating | 1.54% | Equity World Health Care Innovation | 13 |
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.